Gene editing can repair mutations that prematurely halt protein synthesis, resulting in incomplete peptides that cause various diseases. However, other approaches achieve the same effect without ...

Last year’s chemistry Nobel prize was awarded to researchers using AI to study proteins in entirely new ways, and in 2025 ...

Research into how a father’s choices — such as diet, exercise, stress, nicotine use — may transfer traits to his children has ...

This article explores how challenges such as sequence optimization, immune activation and off-target effects are being addressed to enhance the safety, durability and efficacy of RNA therapeutics.

The following discussion is on the use of phosphite as a natural soil fungicide and bio-stimulant for early-season soil fungal control and fast plant growth. What is the difference between phosphite ...

WIRED spoke with DeepMind’s Pushmeet Kohli about the recent past—and promising future—of the Nobel Prize-winning research ...

Here are five medical breakthroughs that gave us hope in 2025. In February, a baby with a rare, often fatal genetic disorder ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Imagine a container of tomatoes arriving at the container terminal in Aarhus. The papers state that the tomatoes are from ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...